Definition And Classification

Disease Overview

  • Inflammation involving mucosal lining paranasal sinuses.
  • Preferred terminology acute rhinosinusitis secondary concurrent nasal mucosa involvement.
  • Acute: Symptom duration <30 days.
  • Subacute: Symptom duration 30-90 days.
  • Chronic: Symptom duration >90 days continuous inflammation.
  • Recurrent Acute: >=4 distinct episodes annually demonstrating complete inter-episode resolution.
  • Acute Bacterial Rhinosinusitis (ABRS): Bacterial superinfection complicating initial viral upper respiratory infection.

Paranasal Sinus Development

Chronological Pneumatization

  • Development timeline predicts infection anatomical site based patient age.
  • Ethmoid And Maxillary: Present, pneumatized at birth. Constitute primary sinusitis sites infants, toddlers.
  • Sphenoid: Pneumatization occurs ages 3-5 years.
  • Frontal: Pneumatization begins ages 6-8 years, reaching full development during adolescence. Frontal sinusitis rare children <10 years.

Etiology And Microbiology

Causative Organisms

  • Viral Pathogens (Most Common): Rhinovirus, Influenza, Adenovirus, Parainfluenza, Coronavirus.
  • Bacterial Pathogens (ABRS): Nontypeable Haemophilus influenzae (~50%), Streptococcus pneumoniae (~30%), Moraxella catarrhalis (~10-20%).
  • Pathogen Shifts: Routine pneumococcal conjugate vaccination shifted prevalence favoring nontypeable Haemophilus influenzae primary ABRS pathogen.
  • Severe/Complicated Disease Organisms: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus anginosus group, anaerobes.

Pathophysiology And Predisposing Factors

Disease Mechanism

  • Infection strictly follows preceding viral upper respiratory infection.
  • Viral infection induces mucosal swelling, localized edema.
  • Edema obstructs narrow (1-3 mm) ostiomeatal complex governing sinus drainage.
  • Nose blowing forcefully propels colonized nasal secretions sterile sinus cavities.
  • Impaired mucociliary clearance traps secretions causing profound stasis.
  • Resulting hypoxic, static environment selectively favors high-titer bacterial overgrowth.

Predisposing Risk Factors

  • Host Factors: Allergic rhinitis (most frequent risk factor).
  • Anatomical Defects: Septal deviation, adenoid hypertrophy, nasal polyps, concha bullosa.
  • Systemic Conditions: Cystic Fibrosis (bilateral polyps), Primary Ciliary Dyskinesia, primary immunodeficiencies.
  • Environmental/Iatrogenic: Tobacco smoke exposure, prolonged nasogastric/nasotracheal intubation blocking sinus ostia.

Clinical Manifestations And Diagnostic Criteria

AAP Diagnostic Criteria (2013)

  • Differentiation simple viral infection from ABRS requires strict clinical criteria.
  • Diagnosis established presence any one three distinct clinical presentations:
    • Persistent Symptoms: Nasal discharge (any quality) or daytime cough >10 days lacking clinical improvement.
    • Severe Onset: High fever >=39°C (102.2°F) concurrent purulent nasal discharge lasting minimum 3-4 consecutive days initial illness.
    • Worsening Course (Double Sickening): Initial viral symptom improvement followed new-onset fever, severe headache, worsening discharge day 6-7.

Clinical Severity Score

Assessment Metrics

  • Total score <8 indicates mild/moderate disease.
  • Total score >=8 indicates severe disease.
Clinical Sign/SymptomAssigned Points
Facial tenderness3
Severe headache (retro-orbital)3
Severe abnormal nasal discharge2
Fever >=38.5°C2
Cough2
Mild headache/Minimal discharge/Congestion1 Each

Evaluation And Investigations

Imaging And Laboratory Assessment

  • Clinical Diagnosis: Sufficient uncomplicated acute sinusitis.
  • Plain Radiographs: Obsolete pediatrics, high false positive/negative rates, not recommended.
  • Contrast-Enhanced Computed Tomography (CT): Gold standard delineating sinus anatomy. Indications strictly reserved suspected orbital/intracranial complications, surgical planning, severe recalcitrant disease.
  • Microbiological Diagnosis: Sinus aspirate culture represents gold standard. Routine aspiration impractical, strictly reserved nonresponsive, highly immunocompromised patients.

Differential Diagnosis

Alternate Etiologies

  • Viral Upper Respiratory Infection: Clear discharge, symptom duration <10 days.
  • Allergic Rhinitis: Seasonal variation, profound nasal eosinophilia, transverse nasal crease.
  • Nasal Foreign Body: Unilateral foul-smelling purulent discharge.

Complications

Anatomical Vulnerability

  • Pediatric sinusitis highly prone anatomical extension secondary extremely thin separating bony walls (lamina papyracea).

Orbital Complications (Chandler Classification)

  • Represents most frequent complication, typically originating ethmoiditis.
  • Stage I (Preseptal Cellulitis): Eyelid edema, erythema. Intact, normal extraocular movement.
  • Stage II (Orbital Cellulitis): Post-septal inflammation. Proptosis, chemosis, marked ophthalmoplegia.
  • Stage III (Subperiosteal Abscess): Purulent collection between lamina papyracea, periorbita. Globe displaced laterally/downward.
  • Stage IV (Orbital Abscess): Purulent collection within intraorbital fat. Imposes severe visual threat.
  • Stage V (Cavernous Sinus Thrombosis): Bilateral progression, cranial nerve III, IV, VI palsies.

Intracranial And Osseous Complications

  • Intracranial Spread: Epidural/Subdural empyema, severe meningitis, brain abscess. Requires emergent broad-spectrum intravenous coverage (Cefotaxime/Ceftriaxone plus Vancomycin, Metronidazole).
  • Osseous Spread: Pott Puffy Tumor (frontal bone osteomyelitis producing doughy subgaleal forehead swelling).

Management Strategies

Medical Therapy Approach

  • Watchful Waiting: Observation 3 additional days permissible strictly patients displaying persistent criteria (Criterion 1) lacking severity.
  • Immediate Pharmacotherapy: Required children exhibiting severe onset or double sickening criteria.

Antibiotic Selection

  • First-Line Therapy: Amoxicillin-clavulanate represents drug choice.
  • Mild/Moderate Disease: Low-dose Amoxicillin-clavulanate (45 mg/kg/day amoxicillin component divided twice daily).
  • Severe Disease/High Resistance Risk: High-dose Amoxicillin-clavulanate (80-90 mg/kg/day amoxicillin component divided twice daily).
  • Penicillin Allergy (Type 1 Hypersensitivity): Levofloxacin (10-20 mg/kg/day).
  • Penicillin Allergy (Non-Type 1 Hypersensitivity): Cefpodoxime, Cefdinir.
  • Severe/Hospitalized Cases: Intravenous Ampicillin-sulbactam, Ceftriaxone, Levofloxacin.
  • Treatment Duration: 10-14 days standard, alternatively 7 days post-complete symptom resolution.

Adjuvant And Surgical Therapy

  • Adjuvant Measures: Normal saline irrigation beneficial clearing viscous secretions. Intranasal steroids offer modest benefit primarily concurrent allergic rhinitis.
  • Contraindicated Adjuvants: Decongestants, antihistamines strictly NOT recommended, severely thicken secretions impairing clearance.
  • Surgical Intervention: Functional Endoscopic Sinus Surgery (FESS) establishes drainage/ventilation. Indications include Chandler Stage III+ orbital complications, intracranial extension, failure maximal medical therapy, underlying severe anatomical defects.